Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags DESTINY-Breast01

Tag: DESTINY-Breast01

Daiichi Sankyo

FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...

ADC Review | Editorial Team
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...

Daiichi Sankyo and AstraZeneca Agree on Global Development and Commercialization for...

ADC Review | Editorial Team
Daiichi Sankyo and AstraZeneca confirmed entering into a global development and commercialization agreement for datopotamab deruxtecan also know as DS-1062, a TROP2 directed DXd...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X